Observational studyEye (London, England)2021
Optical coherence tomography angiography characteristics of choroidal melanoma.
Observational study in Eye (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Advances in multimodal imaging for diagnosis of pigmented ocular fundus lesions.Canadian journal of ophthalmology. Journal canadien d'ophtalmologie · 2024Review
- Review
- Appearance of Tumor Vessels in Patients With Choroidal Osteoma Using Swept-Source Optical Coherence Tomographic Angiography.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study is to evaluate tumour vasculature with optical coherence tomography angiography (OCTA) in malignant choroidal melanoma (CM). MATERIALS AND
methodsPatients with unilateral CM were included in this cross-sectional observational clinical study. Applying OCTA systems operating at 840-nm wavelengths, eyes with CM were imaged. The primary main outcome measures were OCTA images, qualitative evaluation of macular and tumour vasculature, quantitative vascular density (VD), perfusion density (PD) and the foveal avascular zone disruption.
resultsThe study included 11 patients with unilateral CM and contralateral unaffected eyes as the control group. Eyes of 11 patients with CM and contralateral unaffected eyes were imaged before brachytherapy and 5 patients were imaged post brachytherapy. CM is demonstrated dense, tortuous blood vessels, uneven thickness and relatively disorganised intratumoural vasculature. In 11 eyes with CM, the VD and PD in the macular area were significantly lower within affected eyes (131.333 ± 27.807%, 3.152 ± 0.714%, p < 0.0001) than in contralateral eyes (154.208 ± 5.599%, 3.662 ± 0.127%, p < 0.0001). The VD and PD in the tumour area (67.990 ± 34.899%, 1.617 ± 0.847%, p < 0.0001) were significantly lower when compared to the macular area of affected eyes (131.333 ± 27.807%, 3.152 ± 0.714%, p < 0.0001) and the macular area of contralateral eyes (154.208 ± 5.599%, 3.662 ± 0.127%, p < 0.0001). After radiation treatment, the VD and PD in five CM eyes (116.526 ± 7.598%, 2.438 ± 0.358%, p < 0.05) were significantly lower than before treatment (141.544 ± 14.645%, 3.327 ± 0.354%, p < 0.05). Tumour regression after radiation therapy for melanomas was associated with decreased vessel density.
conclusionsOCTA can provide a dye-free, non-invasive, reliable method to monitor a variety of tumours, including CM for growth and vascularity. Upon OCTA, this could be helpful in evaluating the variety of tumour blood vessels before and after brachytherapy to judge the curative effect and whether the tumour recurred. Detection of the characteristic vascular features of CM by OCTA could make OCTA an assuring diagnostic modality to differentiate malignant lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.